Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Invitation to the presentation of SenzaGen's Q3 2026 interim report

By Modular Finance

SenzaGen's report for the third quarter 2026 will be published on November 5, 2026, followed by a live webcast presentation at 10:00 CET on the same day. The presentation will be given by SenzaGen's President and CEO, Peter Nählstedt, with a subsequent Q&A session moderated by Rodney Alfvén, partner at Hallvarsson & Halvarsson.

The presentation will be held in English.

Time: Thursday, Nov 5, 10:00 CET.

Webcast
If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions.
https://senzagen.events.inderes.com/q3-report-2026/register

Teleconference
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.  
https://events.inderes.com/senzagen/q3-report-2026/dial-in

The presentation can also be viewed later on SenzaGen's website: https://senzagen.com/investors/presentations/

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Tel: +46 46-275 62 00

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Tel: +46 46-275 62 00

About us

SenzaGen is a fast‑growing company in the field of non‑animal chemical safety testing. Through ground-breaking innovations that better reflect human biology, the company works toward its vision of advancing and protecting human health while replacing the use of animals in testing. With GLP‑certified laboratories in Sweden and Italy, SenzaGen is driving the shift toward safer and more ethically sustainable testing practices. At the center of the offering is the company’s unique GARD® platform, which combines genomics and machine learning to deliver highly reliable decision‑support data for assessing skin and respiratory sensitization. SenzaGen’s strategy combines commercial focus, regulatory progress, and innovation to support long‑term profitable growth. SenzaGen is headquartered in Lund, Sweden, with subsidiaries in Italy and the United States. For more information, visit www.senzagen.com. 

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser. 

Attachments

Invitation to the presentation of SenzaGen's Q3 2026 interim report

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.